The estimated Net Worth of Joseph H Crabb is at least $659 millier dollars as of 26 November 2018. Dr Crabb owns over 47,500 units of Immucell stock worth over $537,593 and over the last 21 years he sold ICCC stock worth over $66,602. In addition, he makes $54,982 as VP & Chief Scientific Officer at Immucell.
Dr has made over 14 trades of the Immucell stock since 2004, according to the Form 4 filled with the SEC. Most recently he exercised 47,500 units of ICCC stock worth $80,750 on 26 November 2018.
The largest trade he's ever made was exercising 47,500 units of Immucell stock on 26 November 2018 worth over $80,750. On average, Dr trades about 7,263 units every 282 days since 2004. As of 26 November 2018 he still owns at least 141,845 units of Immucell stock.
You can see the complete history of Dr Crabb stock trades at the bottom of the page.
Dr. Joseph H. Crabb Ph.D. is the VP & Chief Scientific Officer at Immucell.
As the VP & Chief Scientific Officer of Immucell, the total compensation of Dr D at Immucell is $54,982. There are 5 executives at Immucell getting paid more, with Michael F. Brigham having the highest compensation of $354,272.
Dr D is 66, he's been the VP & Chief Scientific Officer of Immucell since . There are no older and 10 younger executives at Immucell.
Joseph's mailing address filed with the SEC is PO BOX 746, , OQUOSSOC, ME, 04964.
Over the last 21 years, insiders at Immucell have traded over $168,227 worth of Immucell stock and bought 568,684 units worth $2,330,117 . The most active insiders traders include Jonathan E Rothschild, Norman H Pessin et Joseph H Crabb. On average, Immucell executives and independent directors trade stock every 50 days with the average trade being worth of $22,979. The most recent stock trade was executed by David Cunningham on 13 June 2022, trading 1,000 units of ICCC stock currently worth $8,000.
immucell corporation is a biotechnology company based out of portland maine. immucell's focus is to create scientifically-proven and practical products that result in a measurable economical impact on animal health and productivity in the dairy and beed industries.
Immucell executives and other stock owners filed with the SEC include: